Open Access

The contribution of medical physics to nuclear medicine: a physician's perspective

EJNMMI Physics20141:3

DOI: 10.1186/2197-7364-1-3

Received: 12 February 2014

Accepted: 20 February 2014

Published: 1 May 2014


This paper is the second in a series of invited perspectives by four pioneers of nuclear medicine imaging and physics. A medical physicist and a nuclear medicine clinical specialist each take a backward look and a forward look at the contributions of physics to nuclear medicine. Here is a backward look from a nuclear medicine physician's perspective.


Nuclear medicine Physics History

He who does not doubt, does not investigate, does not perceive; and he who does not perceive, remains in blindness and error”

Al-Ghazali (1058–1111 a.c.), theologian, jurist, philosopher, cosmologist, psychologist and mystic

The introduction of radioactive tracers to clinical medicine can be traced to the late 40 s [13]. From its inception, physicians and physicists made use of purposely developed detection instruments and radionuclides in order to (a) further the understanding of the underlying mechanisms of disease in man and (b) to investigate the earliest manifestations of pathologies. To diagnose early on and to treat if possible were mutual aims of both physicians and physicists. To underline, the contribution of scientists and physicists to the development of Nuclear Medicine has been not just major but disruptive and of fundamental importance. The very first applications preceded the previously mentioned by half a century (Table 1).
Table 1

The pioneers of nuclear medicine



Wilhelm C. Roentgen

German physicist

1845 to 1923



Antoine H. Becquerel

French physicist

1852 to 1908


Polonium, radium,thorium

Marie Sklodowska Curie

French physicist

1867 to 1934


Tracer principle

Georg V. Hevesy

Hungarian chemist

1885 to 1966


Circulation times

Hermann L. Blumgart

German doctor

1895 to 1977



Johannes W. Geiger

German physicist

1882 to 1945


Walther Mueller

German physicist

1905 to 1979



Ernest O. Lawrence

American physicist

1901 to 1958

November 12, 1936

Visiting patients at his thyroid clinic at Mass General Hospital, the physician JH Means, M.D., poses a most relevant question. In his mind was already the understanding of the role and importance of iodine metabolism of the thyroid and the possibility to measure it non-invasively in vivo. RE Evans, Ph.D., rose to the challenge with a seminar pronouncement:

JH Means M.D.: ‘Is there a radioisiotope of iodine?’

Robley Evans, Ph.D.: Mass. Inst. Techn.: ‘We can make some’.

This seminal encounter possibly marks the development of what was to become known as Nuclear Medicine (Table 2, Figure 1). It is the perfect example of the interdisciplinary thinking which was to permeate and characterise the development of this speciality. It also represents the ideal setup, where an identified problem, namely, the investigation of thyroid physiopathology, led to the development of a new investigative tool (the radionuclide). It would take many years indeed before another ‘magic bullet’ was to be identified and widely applied. If specificity is intended by such a magic bullet, receptor ligands such as those targeting the dopamine and somatostatin receptors and most recently those ligands targeting the misfolded amyloid protein, are good examples of the progress achieved.
Figure 1

Glenn Seaborg (middle) and wife (left), together with the author (right) at a SNM meeting in the late 1990s. Seaborg won the 1951 Nobel Prize for Chemistry, discovered over 100 isotopes, advised 10 Presidents of the USA and was Chairman of the USA Atomic Energy Commission for 10 years.

Table 2

The early years of nuclear medicine


First radioactive 128I

Enrico Fermi

Italian physicist

1901 to 1954


Production of 99mTc

Emilio G. Segre

Italian physicist

1905 to 1989


First therapy with 32P

John H. Lawrence

American physicist

1904 to 1991


Discovery of 131I

Glenn Seaborg

American chemist

1912 to 1999


Therapy of benign thyroid disease

Saul Hertz

American physician

1905 to 1950


Robley D. Evans

American physicist

1907 to 1995


First therapy of thyroid cancer

S. M. Seidlin

American physician

1895 to 1955


Leo D. Marinelli

American physicist

1886 to 1995


First therapy of thyroid


Carcinoma in Europe

Cuno Winkler

German physician

1919 to 2003


Eric E. Pochin

British physician

1909 to 1990

Whilst on the topic of interdisciplinarity, it is opportune to underline that not only physicists greatly contributed to the development of Nuclear Medicine. This equally applied inter alia to engineers, chemists and radiopharmacists. Gopal Subramanian with a degree in chemical engineering introduced 99mTc labelled phosphonates for bone scanning; Hal Anger as an electrical engineer and biophysicist developed the Anger gamma camera; Roger Ekins, also a biophysicist, developed the saturation analysis/radioimmunoassay methodology (Table 3). Physicists turned physiologist developed and emphasised the need for elegance and simplicity in quantitative measurements.
Table 3

Twenty-five years of seminal discoveries


Rectilinear scanner

Benedict Cassen

American physicist

1902 to 1972


CBF with radio krypton

Niels Lassen

Danish physician

1926 to 1997


Anger gamma camera

Hal O. Anger

American engineer

1920 to 2005



Rosalin S. Yalow

American physicist

1921 to 2011


Solomon Berson

Americal physician

1918 to 1972


Saturation analysis

Roger Ekins

British biophysicist

b. 1936


Tc-99 m generator

Paul Harper

American surgeon

1915 to 2005


Katherine Lathrope

American physicist

1915 to 2005



David Kuhl

American physician

b. 1929



Gopal Subramanian

American chemist

1953 to 2000



Michel Ter-Pogossian

American physicist

1925 to 1996


Michael Phelps

American biophysicist

b. 1939

From the preceding pgraph, it is clear that fundamental discoveries spanned a period of a century. In the space available for this short piece, it is simply not possible to give due consideration to all those many eminent scientists who developed the field. So I shall focus on the three seminal physics developments which fundamentally changed the practice and future of Nuclear Medicine: the introduction of the rectilinear scanner, the development of the gamma camera and, finally, the design of the first single-photon emission computed tomography (SPET), positron emission photography (PET) and PET/computed tomography (CT) instruments.

Surface counting had been an important milestone in the clinical development of the radioactive tracer method. It was used early on by Norman Veal and others in mapping the placenta, the thyroid and the pericardium. This was laborious, a manual-driven process and rather time-consuming. It was difficult to perceive much more than the simplest outlines of organs, and yet, quantitative measurements were already taking place.

The relationship between physicists and physicians has always been most interesting. A healthy diffidence between both experts was often present and wonderfully illustrated from the following extract, taken from the outstanding chronology authored by Marshall Brucer, the first President of the Society of Nuclear Medicine (USA) and Chairman of the medical division of Oakridge Institute of Nuclear Studies from 1948 to 1962. And one can read in page 291: ‘…three months after the London meeting (the first meeting at University College London, on 29th July 1950, where data from 131I therapy was discussed)’, Sam Seidling asked: ‘If a metastasis has high uptake, we can destroy it. Now, for God’s sake, when will physicists learn to measure 131I uptake?’. Leo Marinelli murmured: ‘As soon as physicians decide how much uptake is high’.

Benedict Cassen changed all this with his discovery of the rectilinear scanner in 1950. Born in New York in 1902, he graduated in physics and mathematics from the Royal College of Science in London in 1927. He moved to the California institute of Technology in 1930. Imaging the thyroid, he reported first results in 1950. The radioactive tracer method would forever be linked to imaging, for better or for worse. Single-head, dual-head, 3-inch or 5-inch rectilinear scanners and whole-body scanners became routine imaging instruments for 2D organ imaging and counting, dominating for some 30 years Nuclear Medicine applications well into the late 80s, as new tracers became available.

Whilst brilliant individual scientists made major contributions to medicine, institutions and or societies have a habit of getting it wrong. In the late 40 s, much debate and thought went into what role a medical physics department should have in a hospital. To quote an example: ‘…Any one radio-element investigation may be too short lived to justify the provision by the department concerned of the best apptus for the job’. [4]. Whilst Cassen had already proven that this viewpoint was completely wrong, how would Hal Anger comment on the on the previously mentioned discussion?

US patent 3,011,057 in 1961

Nuclear Medicine was to change forever with the mentioned patent, defining the Anger gamma camera. It is truly astonishing that this technology, still in worldwide use today, has outlived over half a century of technological breakthroughs and progress! In modern times, there is probably no other example of such a long lasting instrumentation breakthrough.

Hal Oscar Anger (Figure 2) was born on the 20th of May 1920, in Denver, USA. He graduated as an electrical engineer. His innovative career spanned from radar jamming equipment to radiation detector devices, culminating with his seminal invention of the imaging device still in use today. His camera was presented at the 1958 meeting of the Society of Nuclear Medicine and led to an explosion of commercial exploitations. The history of the patent itself would merit a septe chapter. He died on October 21, 2005, in Berkeley. No writings can give sufficient justice to Anger's innovative genius and the impact he has had worldwide on millions of patients investigated with his seminal instrument.
Figure 2

Hal Oscar Anger (1920 to 2005).

It would take some 30 years before 3D Imaging became an integral part of the development of Nuclear Medicine. And one has to give proper due to a medical scientist, David Kuhl (Figure 3), the originator of single-photon emission tomography. Born in St. Louis, Missouri in 1929, David E. Kuhl graduated in medicine at UPENN in 1955. In 1964, David Kuhl and Roy Edwards developed the Mark II emission tomographic scanner, starting the field of cross-sectional tomographic imaging. Kuhl went to develop the technique of SPET - truly ahead of its time and ahead of the development of the CT scanner (1973). Should one write a history of missed Nobel awardees? Mark II was followed by Mark IV and a number of subsequent improvements.
Figure 3

David Kuhl (born in 1929, retired in 2011). Image taken during presentation of the 2009 Japan Prize Award, attended by Emperor Akihito. This prestigious prize was introduced in 1985 to award scientists who contribute to the development of science and technology.

Single-slice SPET imaging was subsequently superseded by whole-volume SPET imaging, with the introduction of the rotating gamma camera (Anger's device, shaping de novo the clinical applications of the radioactive tracer method). Without SPET, nuclear cardiology, and less so, neurotransmission imaging would have not risen to the clinical pre-eminence these modalities reached in the last 15 years. SPET became a truly worldwide available technology, supported by a range of useful radiopharmaceuticals.

Modern technologies (SPET, SPET/CT, PET, PET/CT and PET/MR)

The beginnings and development trends of positron emission tomography are outlined in Table 4. Again, constraints on space prevent a detailed analysis. Suffice to say that for a physician, interested in patient care and management, it took a rather long time before clinical useful applications began to emerge [57]. It would take the development and final availability of 18F labelled glucose, which made positron emission tomography a clinically useful tool. Between the development of the first PET system in 1973 by Michael Phelps and the approval by the FDA of 18F labelled glucose, 24 years would have elapsed (Table 4).
Table 4

The history of PET


First use of NaI probes for positron detection in brain

William Sweet and Gordon Brownell


First description of radon equations for image reconstruction

Alan M. Cormack


Description of CT scanner

Godfrey N. Hounsfield


First PET tomograph

Michael E. Phelps


First commercial PET scanner



First BGO-based scanner

Chris Thompson


14C Deoxyglucose

Louis Sokoloff


18F Fluorodeoxyglucose

Tatsuo Ido


Present synthesis of FDG

Kurt Hamacher


Commercial cyclotron development



FDA approves FDG as radiopharmaceutical



PET/CT prototype

David Townsend and Ron Nutt


Lutetium orthosilicate (LSO)



Medicare reimburses for staging NSCLC, SPN, colorectal ca, HD and NHD, melanoma, hibernating myocardium and TLE






Health technology assessments (HTA) begin

To complete this brief review, we end with David Townsend, Ph.D., who gave us the most significant development in medical imaging in the last 10 to 15 years. The PET/CT prototype, attributed to Townsend and Nutt (Figure 4), then President of CPS Innovations, was named by TIME Magazine as the medical invention of the year 2000. A hugely impressive development, bringing human anatomy and biochemistry onto a combined 3D map, this technology was instantly adopted by the medical community as an essential tool for early staging and monitoring of human disease. No hospital facility today can bypass the availability of a PET/CT system for appropriate patient management.
Figure 4

David W Townsend (2nd left) and Ronald Nutt (2nd right). The IEEE Medal for Innovations in Healthcare Technology was given to David W Townsend (2nd left) and Ronald Nutt (2nd right). Photograph taken with Moshe Kam (IEEE President Elect, left) and Pedro Ray (IEEE President, right).

What about PET/MR? Time will tell; its adoption by the medical community will take much longer. But the input of physics computing and engineering will remain vital for the future development of this innovative speciality. This will be ever more relevant as the demands posed by multimodality imaging technologies and the need for true quantitative and reproducible measurements are widely felt. This is especially relevant in the increasing need for the monitoring of interventions, being medical, surgical or pharmacological, applied to an individual patient. Whilst the overtly simplistic aims of personalised medicine are being reassessed, patient specific interventions will grow, and with it, the growth of physics in the field is assured.


Authors’ Affiliations

Institute of Nuclear Medicine (T5), University College London NHS Trust Hospitals


  1. Marshall B: A chronology of nuclear medicine. Edited by: Buntaine RR. London, UK: Heritage Publications; 1990. ISBN 0-9625674-O-XGoogle Scholar
  2. Feld M, DeRoo M: History of nuclear medicine in Europe. Edited by: Schicha H, Bergdolt K, Ell PJ. Schattauer Verlag; 2003. ISBN 3-7945-2234-6Google Scholar
  3. 25 Years of the EANM. Publisher: European Association of Nuclear Medicine; 2012.
  4. The Organisation of Hospital Physics Departments: III. The broader view of hospital physics. Br J Radiol 1949, 22: 596–598. 10.1259/0007-1285-22-262-596View ArticleGoogle Scholar
  5. Wagner HN Jr., Burns HD, Dannals RF, Wong DF, Langstrom B, Duelfer T, Frost JJ, Ravert HT, Links JM, Rosenbloom SB, Lukas SE, Kramer AV, Kuhar MJ: Imaging dopamine receptors in the human brain by positron tomography. Science 1983, 221: 1264–1266. 10.1126/science.6604315View ArticlePubMedGoogle Scholar
  6. Lamberts SWJ, Bakker WH, Reubi J-C, Krenning EP: Somatostatin receptor imaging in the localization of endocrine tumours. N Engl J Med 1990, 323: 1246–1249. 10.1056/NEJM199011013231805View ArticlePubMedGoogle Scholar
  7. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergström M, Savitcheva I, Huang GF, Estrada S, Ausén B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Långström B: Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004, 55: 306–319. 10.1002/ana.20009View ArticlePubMedGoogle Scholar


© Ell; licensee Springer. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.